三葉草生物-B(02197.HK)與聯合國兒童基金會訂立疫苗供應協議
格隆匯12月7日丨三葉草生物-B(02197.HK)公吿，於2021年12月7日，公司的全資附屬公司Clover Biopharmaceuticals (HongKong) Co., Limited與聯合國兒童基金會訂立長期協議，以承諾於2022年末向COVAX機制提供最多414百萬劑公司的COVID-19候選疫苗SCB-2019(CpG1018加鋁佐劑)。
於2021年6月，三葉草香港公司與GAVI(全球疫苗免疫聯盟)訂立了預購協議，以透過COVAX機制就採購提供最多414百萬劑SCB2019(CpG1018加鋁佐劑)。疫苗供應協議將促成GAVI預購協議的實施，一旦公司的COVID-19候選疫苗獲批列入世界衞生組織(WHO)的緊急使用清單，COVAX機制參與國將可通過UNICEF獲得該COVID-19候選疫苗。
UNICEF在全球一些最貧困的地方開展工作，致力於幫助世界上最弱勢的兒童。UNICEF在190個國家和地區為每個角落的兒童提供幫助，為每個人創造一個更美好的世界。
COVAX是"獲取COVID-19工具加速計劃"的疫苗工作支柱，其乃一項開創性的全球合作，旨在加速COVID-19試驗、治療及疫苗的開發、生產和公平獲取。COVAX由GAVI、CEPI(流行病防範創新聯盟)及WHO聯合領導。
COVAX機制，指COVID-19疫苗實施計劃，乃由UNICEF、 GAVI, the Vaccine Alliance、WHO、CEPI 等聯合牽頭的旨在公平獲得COVID-19疫苗的一項全球倡議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
